Antibodies: Top pre-clinical and clinical ADC programs from Pfizer
#Antibodies: Do you agree that novel research concepts have the potential to transform ADC development?
Dr Hans-Peter Gerber, now a Executive Director of BioConjugate Discovery and Development at Pfizer gave a review of how these novel research concepts for studying ADC targets, targeting vehicles, linkers and payloads could and perhaps are impacting this industry.
Pre-clinical and clinical ADC programs
- Differences in the mechanism of action between calicheamicin and tubulin inhibitor based ADCs
- Preclinical development of an ADC targeting the oncofetal antigen 5T4, expressed on tumor initiating cells in a variety of solid tumors
- Phase II/III Clinical update on CMC-544, an anti-CD22 calicheamicin conjugate developed in NHL
Follow the link below for the presentation slides delivered at the 2011 European Antibody Congress, and find out the details!
Do you want to find out more?